Who We Are
Developing Proprietary Biosimilar Pipeline
We are developing proprietary biosimilar pipeline through process innovation, unwavering commitment to quality and its own manufacturing infrastructure.
Collaboration & Licensing of Innovative Biologics
We licence-in innovative new molecules for co-development that we believe offer benefits over current standards of care.
Contract Manufacturing Services
We provide high quality, reasonable priced Contract Development and Manufacturing Services to accelerate the development programs of select partners.
Founded in 2012, JHL is an innovator in biopharmaceuticals that utilizes breakthrough engineering and process technologies to provide high quality and affordable biosimilar medicines to patients in need.
|June 2018||Rituximab biosimilar received CDE approval for Phase I + III CTA filing in China|
|May 2018||Completed US$106m convertible bond|
|March 2018||Phase I EU CTA approval for JHL1922 received|
|February 2018||Phase I EU CTA approval for JHL1149 received|
|December 2017||Phase I CTA submitted in the EU for JHL1149 and JHL1922
JHL named #19 on Deloitte’s 2017 Fast 500 Ranking
|April 2017||CTA for use of JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by for review|
|December 2016||Announced strategic biologics alliance with Sanofi|
|February 2016||Announced mechanical completion of its Wuhan Biopharmaceutical manufacturing facility
JHL1101 EU clinical trial approval
|June 2014||Closed US$35 million Series B financing|
JHL is strong and flexible like the stalks of the bamboo. The strength comes from everyone’s expertise and ability to work together to meet the common goal of making world-class biopharmaceuticals affordable and accessible to all patients globally. The flexibility comes from being able to adjust to situations to resolve challenges that we may face.